

Martin Eklund

List of Publications by Citations

Source: <https://exaly.com/author-pdf/15625/martin-eklund-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,193
citations

22
h-index

46
g-index

103
ext. papers

3,460
ext. citations

9
avg, IF

5.02
L-index

#	Paper	IF	Citations
85	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018 , 50, 928-936	36.3	340
84	Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology, The</i> , 2015 , 16, 1667-76	21.7	228
83	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey. <i>PLoS ONE</i> , 2020 , 15, e0238217	3.7	164
82	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology, The</i> , 2020 , 21, 222-232	21.7	154
81	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015 , 68, 139-46	10.2	123
80	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	102
79	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 57-63	6.2	73
78	Population-based screening for cancer: hope and hype. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 550-65	5.4	64
77	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
76	Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. <i>Annals of Internal Medicine</i> , 2014 , 160, 145	8	60
75	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018 , 9, 2256	17.4	57
74	External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. <i>JAMA Oncology</i> , 2020 , 6, 1581-1588	13.4	55
73	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2018 , 74, 722-728	10.2	49
72	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>European Urology</i> , 2018 , 74, 204-210	10.2	47
71	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015 , 75, 1467-74	7.4	43
70	Comparison of a Deep Learning Risk Score and Standard Mammographic Density Score for Breast Cancer Risk Prediction. <i>Radiology</i> , 2020 , 294, 265-272	20.5	42
69	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2021 , 385, 908-920	59.2	42

68	Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study. <i>The Lancet Digital Health</i> , 2020 , 2, e468-e474	14.4	40
67	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , 2018 , 4, 707-710	5.1	30
66	Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. <i>Acta Oncologica</i> , 2016 , 55, 45-51	3.2	24
65	A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml. <i>European Urology</i> , 2014 , 65, 1184-90	10.2	24
64	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , 2021 , 34, 660-671	9.8	22
63	Factors Contributing to Healthcare Professional Burnout During the COVID-19 Pandemic: A Rapid Turnaround Global Survey 2020 ,		20
62	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018 , 142, 741-746	7.5	19
61	Risk of Prostate Cancer in Men Treated With 5 α -Reductase Inhibitors-A Large Population-Based Prospective Study. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1216-1221	9.7	18
60	Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial. <i>BMC Medical Research Methodology</i> , 2018 , 18, 3	4.7	18
59	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019 , 144, 1195-1204	7.5	18
58	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.. <i>Nature Medicine</i> , 2022 ,	50.5	14
57	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 137-142	6.2	14
56	The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky067	4.6	13
55	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. <i>JAMA Network Open</i> , 2019 , 2, e1914689	10.4	11
54	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. <i>Lancet Oncology</i> , 2021 , 22, 1240-1249	21.7	11
53	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. <i>BMJ Open</i> , 2019 , 9, e027816	3	10
52	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 777-786	5.1	10
51	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , 2017 , 3, 526-528	5.1	10

50	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1899-1908	2.2	10
49	The economic burden of prostate cancer - a Swedish prevalence-based register study. <i>BMC Health Services Research</i> , 2020 , 20, 448	2.9	9
48	Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	9
47	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019 , 2, 490-496	6.7	8
46	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. <i>European Urology Oncology</i> , 2020 , 3, 640-647	6.7	8
45	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. <i>European Urology Focus</i> , 2018 , 4, 385-387	5.1	7
44	Range of Radiologist Performance in a Population-based Screening Cohort of 1 Million Digital Mammography Examinations. <i>Radiology</i> , 2020 , 297, 33-39	20.5	7
43	The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. <i>BMJ Open</i> , 2019 , 9, e027958	3	6
42	Predictors of participation in risk-based prostate cancer screening. <i>PLoS ONE</i> , 2018 , 13, e0200409	3.7	6
41	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). <i>Journal of the National Cancer Institute</i> , 2021 , 113, 632-640	9.7	6
40	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , 2019 , 14, e0211918	3.7	5
39	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. <i>Trials</i> , 2020 , 21, 579	2.8	5
38	Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. <i>Breast Cancer Research</i> , 2018 , 20, 14	8.3	5
37	Prognostic factors for digital range of motion after intrasynovial flexor tendon injury and repair: Long-term follow-up on 273 patients treated with active extension-passive flexion with rubber bands. <i>Journal of Hand Therapy</i> , 2019 , 32, 328-333	1.6	5
36	Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. <i>World Journal of Urology</i> , 2021 , 39, 1797-1804	4	5
35	Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. <i>European Urology Focus</i> , 2021 , 7, 546-553	5.1	5
34	The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13,	19.4	5
33	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2020 , 73, 630-635	3.9	4

32	E-Science technologies in a workflow for personalized medicine using cancer screening as a case study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017 , 24, 950-957	8.6	3
31	Association between PSA density and prostate cancer in men without significant MRI lesions. <i>BJU International</i> , 2020 , 125, 763-764	5.6	3
30	Artificial Intelligence in Magnetic Resonance Imaging-based Prostate Cancer Diagnosis: Where Do We Stand in 2021?. <i>European Urology Focus</i> , 2021 ,	5.1	3
29	Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 120-127	6.2	3
28	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. <i>PLoS ONE</i> , 2019 , 14, e0218280	3.7	2
27	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA \leq ng/ml. <i>Scandinavian Journal of Urology</i> , 2020 , 54, 1-6	1.6	2
26	Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. <i>BMC Urology</i> , 2017 , 17, 92	2.2	2
25	Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gröbberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-46. <i>European Urology</i> , 2018 , 74, e35-e36	10.2	2
24	The importance of study design in the application of artificial intelligence methods in medicine. <i>Npj Digital Medicine</i> , 2019 , 2, 101	15.7	2
23	Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps. <i>European Urology Focus</i> , 2021 , 7, 687-691	5.1	2
22	Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 478, 1109-1116	5.1	2
21	Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort.. <i>BJUI Compass</i> , 2022 , 3, 173-183	0.9	1
20	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 299-306	1.6	1
19	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. <i>European Urology Open Science</i> , 2021 , 24, 11-16	0.9	1
18	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.. <i>European Urology Open Science</i> , 2022 , 38, 32-39	0.9	1
17	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. <i>Bioinformatics</i> ,	7.2	1
16	Clinical trial design during and beyond the pandemic: the I-SPY COVID trial.. <i>Nature Medicine</i> , 2022 ,	50.5	0
15	Detection of perineural invasion in prostate needle biopsies with deep neural networks.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022 , 1	5.1	0

14	Reply to Ola Bratt and Anna Everholm Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Gröberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2017.12.028 . <i>European Urology</i> , 2018 , 74, e10-e11	10.2
13	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. <i>BMC Urology</i> , 2019 , 19, 73	2.2
12	Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Gröberg H et al. <i>Lancet Oncology</i> . 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. <i>World Journal of Urology</i> , 2017 , 35, 895-896	4
11	Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) ≥ prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 284-284	2.2
10	Response to Carter et al. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa016	4.6
9	Reply to Erik Rud, Peter Lauritzen, and Eduard Baco Letter to the Editor re: Henrik Gröberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>Eur Urol</i> 2018;74:722-8. <i>European Urology</i> , 2019 , 75, e181-e185	10.2
8	Response to Walsh. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 748	9.7
7	Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 457-464	6.2
6	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. <i>European Urology Open Science</i> , 2021 , 24, 43-51	0.9
5	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey 2020 , 15, e0238217	
4	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey 2020 , 15, e0238217	
3	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey 2020 , 15, e0238217	
2	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey 2020 , 15, e0238217	
1	Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.. <i>Scandinavian Journal of Urology</i> , 2022 , 1-7	1.6